Kazia Therapeutics (KZIA) News Today → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free KZIA Stock Alerts $0.26 +0.01 (+4.00%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29, 2024 | americanbankingnews.comKazia Therapeutics Limited (NASDAQ:KZIA) Sees Large Decline in Short InterestMay 24, 2024 | finanznachrichten.deKazia Therapeutics Limited: Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price RequirementMay 23, 2024 | prnewswire.comKazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price RequirementMay 1, 2024 | prnewswire.comKAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTSMarch 20, 2024 | morningstar.comKazia Therapeutics Ltd ADR KZIAMarch 16, 2024 | finance.yahoo.comKZIA Apr 2024 2.500 callMarch 13, 2024 | prnewswire.comKazia announces presentation of new data at AACR Annual MeetingFebruary 21, 2024 | msn.comWhat's Going With Australia-Based Cancer Firm Kazia Therapeutics On Wednesday?February 21, 2024 | finanznachrichten.deKazia Therapeutics Limited: Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointFebruary 21, 2024 | finance.yahoo.comKazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointFebruary 21, 2024 | prnewswire.comKazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointFebruary 19, 2024 | thestreet.comKazia Therapeutics LimitedFebruary 14, 2024 | wsj.comKazia Therapeutics Ltd. ADRFebruary 13, 2024 | nasdaq.comViking Therapeutics, Inc. Common Stock (VKTX)January 18, 2024 | finance.yahoo.comKAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTSDecember 15, 2023 | msn.comKazia Therapeutics files to sell 591,697 ADSs for holdersDecember 5, 2023 | finance.yahoo.comKazia Therapeutics Announces Closing of $2 Million Registered Direct OfferingDecember 1, 2023 | marketwatch.comKazia Therapeutics Shares Tumble on $2 Million Direct OfferingDecember 1, 2023 | markets.businessinsider.comKazia Therapeutics Announces Registered Direct Offering - Quick FactsDecember 1, 2023 | finance.yahoo.comKazia Therapeutics Announces $2 Million Registered Direct OfferingNovember 29, 2023 | markets.businessinsider.comKazia Therapeutics Enters Non-binding LOI For Paxalisib Rights Outside Of OncologyNovember 29, 2023 | msn.comKazia stock jumps after proposed license deal for paxalisib outside oncologyNovember 29, 2023 | marketwatch.comKazia Therapeutics Signs Letter of Intent for Paxalisib Development, CommercializationNovember 29, 2023 | finance.yahoo.comKAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGYNovember 21, 2023 | finance.yahoo.comKAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGNovember 20, 2023 | msn.comKazia Therapeutics gets deficiency notice from NasdaqNovember 18, 2023 | finance.yahoo.comKazia Therapeutics Limited's (NASDAQ:KZIA) large institutional owners must be happy as stock continues to impress, up 28% over the past weekNovember 15, 2023 | finance.yahoo.comKAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGNovember 1, 2023 | markets.businessinsider.comKazia Provides Preliminary Update From Phase 2 Study Of Paxalisib In Primary CNS Lymphoma; Stock UpNovember 1, 2023 | msn.comKazia issues update on paxalisib study in CNS lymphoma patientsNovember 1, 2023 | finance.yahoo.comKAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMAOctober 23, 2023 | finance.yahoo.comKAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDYOctober 6, 2023 | marketbeat.comTrading was temporarily halted for "KZIA" at 07:10 PM with a stated reason of "News pending."October 5, 2023 | msn.comKazia Therapeutics Limited - ADR (KZIA) Price Target Increased by 7.17% to 1.08October 5, 2023 | finance.yahoo.comKAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGSSeptember 29, 2023 | finance.yahoo.comKAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETINGAugust 3, 2023 | msn.comKazia Therapeutics Limited - ADR (KZIA) Price Target Decreased by 12.12% to 1.15July 7, 2023 | msn.comTraders Digest Strong Jobs Data, Fed Minutes, Fueling Premarket Losses for US Equity FuturesJuly 6, 2023 | msn.comWhat's Going On With Kazia Therapeutics Stock Today?July 6, 2023 | marketwatch.comKazia Therapeutics Shares Higher Premarket on Key FDA Designation >KZIAJuly 6, 2023 | msn.comKazia jumps as FDA awards Fast Track tag for lead programJuly 6, 2023 | finance.yahoo.comKAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPYJuly 4, 2023 | finance.yahoo.comInsider Stock Buying Reaches AU$1.1m On Kazia TherapeuticsJune 8, 2023 | finance.yahoo.comKAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMAMay 25, 2023 | finance.yahoo.comKAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOTMay 1, 2023 | proactiveinvestors.comKazia Therapeutics appoints Dr John Friend as new CEOApril 14, 2023 | finance.yahoo.comKAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENTApril 4, 2023 | finance.yahoo.comKAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETINGApril 3, 2023 | proactiveinvestors.comKazia Therapeutics to present new pipeline molecule data at AACR 2023March 6, 2023 | proactiveinvestors.comKazia Therapeutics forms clinical collaboration for Australian Phase 2 study of paxalisib, targeting childhood cancers Get Kazia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter. Email Address This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. KZIA Media Mentions By Week KZIA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KZIA News Sentiment▼0.780.76▲Average Medical News Sentiment KZIA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KZIA Articles This Week▼30▲KZIA Articles Average Week Get Kazia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: THAR News PTPI News NEXI News ALZN News ARTL News CLVR News GNPX News CPHI News NBY News CING News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KZIA) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kazia Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
